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Synthesis and Characterization of Photoaffinity Labelling reagents 
Towards the Hsp90 C-terminal Domain 
Binto Simon,a Xuexia Huang,a Huangxian Ju, b Guoxuan Sun a and Min Yang*a 
Glucosyl-novobiocin-based diazirine photoaffinity labelling reagents (PALs) were designed and synthesized to probe the 
Hsp90 C-terminal domain unknown binding pocket and structure-activity relationship. Five PALs were successfully 
synthesized from novobiocin in six consecutive steps employing a phase transfer catalytic glycosylation. Reactions were 
monitored and guided by analytical LC/MS which led to different strategies of adding either PAL precursor or sugar moiety 
first. The structures and bonding linkages of these compounds were characterised by various 2D-NMR spectroscopy and MS 
techniques. The synthetic technique provides powerful probes for unknown protein binding pocket. 
Introduction 
Heat Shock Protein 90 kDa (Hsp90) is a molecular chaperone 
involved in folding up to 200 proteins with the assistance of 20 
co-chaperones.1 It has been the target of research in genetics 
and epigenetics,2 neurodegeneration3 and cell mobility.4 Hsp90 
is particularly important for cancer cell survival.5, 6 So far 
seventeen Hsp90 inhibitors have been developed to various 
stages of clinical trials, however, candidates were suspended at 
different clinical stages.7,8 While these results validate Hsp90 
inhibition as a relevant anti-cancer strategy, there is no FDA-
approved drug.1, 9, 10, due to the high cytotoxicity from N-
terminal domain targeting inhibitors. 
Hsp90 consists of three domains: an N-domain that contains 
an ATP, drug-binding site and co-chaperone-interacting motifs; 
an M-domain for client proteins and co-chaperones; and a C-
terminal domain (CTD) contains a dimerization MEEVD motif.11 
Inhibition of the Hsp90CTD decreases chaperone dimerization, 
diminishes ATPase activity and impairs the formation of the 
Hsp90 protein complex. Novobiocin based CTD inhibitors have 
shown some superior activity against various cancer cell lines in 
apoptosis12 or proliferation13 compared to N-terminal 
inhibitors. Indeed, CTD inhibitors have attracted significant 
attention recently.10, 14 
Due to the lack of a high resolution crystal structure, however, 
the binding site and structure-activity relationship (SAR) of 
Hsp90CTD is still unclear. Most high resolution Hsp90 crystal 
structure does not contain CTD. Only 4 Hsp90 crystals reported 
low resolution CTD: 2IOQ (E. coli.),15 2CG9 (Yeast),11 2O1U 
(Dog)16 and 3Q6N (Human, which has 18 amino acid residues 
missing in the CTD).17 Previous research indicated a few possible 
locations for the binding pockets18, 19 in CTD, however, no 
confirmation has been obtained. Experimental-based SAR can 
provide limited guidance in drug design (Fig. 1A), in-depth 
understanding of the exact binding of ligand molecules to 
individual amino acid residues in the polypeptide is urgently 
required. 
Previously we demonstrated that the single glycosylation the 4'-
hydroxyl group of novobiocin (Fig. 1A) could increase its anticancer 
activity20, 21 via binding to the Hsp90CTD22. Although protein 
modelling data indicate the formation of strong hydrogen bonds with 
Hsp90CTD peptides, the exact binding details is not clear.20 We 
hereby designed and synthesized five glucosyl-novobiocin (Glc-Nov, 
Fig. 1B) based trifluoromethyl diazirine-type photoaffinity labelling 
reagents (PALs, 1-5) to probe the binding site of Hsp90CTD.  
a. Department of Pharmaceutical & 
Biological Chemistry, The School of 
Pharmacy, University College London, 
London WC1N 1AX, UK Email: 
min.yang@ucl.ac.uk 
b State Key Laboratory of Analytical Chemistry 
for Life Science, School of Chemistry and 
Chemical Engineering, Nanjing University, 
Nanjing 210023, P.R. China. Fax/Tel.: +86 25 
89683593 
Electronic Supplementary Information (ESI) 
available: NMR spectra & table, LC-MS 
spectra. See DOI: 10.1039/x0xx00000x 
 2 | J. Name., 2012, 00, 1-3 This journal is © The Royal Society of Chemistry 20xx 
 
Figure. 1 Experimental based Hsp90CTD SAR (A) and five PALs (B) 
These five compounds were designed to probe the binding of 
sugars (4'-glucose or 7'-noviose) with Hsp90CTD. Compound 1 
mimics Glc-Nov with the PAL in the 4'-OH position to probe the 4'-O-
glucose moiety binding sites.  Compound 2 mimics Glc-Nov with the 
PAL in the 7'-OH and glucose in the 4'-OH positions respectively. 
Compound 3 mimics novobiocin with the PAL in the 7'- OH position 
to probe the 7'-O-noviose moiety binding sites in the absence of the 
4'-O-glucose moiety. Compound 4 tests the potential binding in the 
2'-O position and compound 5 tests the binding site with only the PAL 
in the 4'-O position, but no substitution on the 7'-OH group. 
Trifluoromethyl diazirine has an excellent chemical stability and is 
highly resistant toward a number of factors such as temperature, 
nucleophiles, acidic and basic conditions and oxidizing/reducing 
reagents. The activation by UV (350 nm) yields an extremely reactive 
flexible carbene, which can insert into C-H, N-H and O-H bonds23 with 
low non-specific binding 24. 
Results & Discussion 
Synthesis of compound 1 was achieved by reaction of 
novobiocin with diazirine bromide (6) in a polar aprotic solvent 
(DMF). Complete NMR assignment of all individual proton and 
carbon resonances has been achieved using 1H, 13C-NMR, DEPT-
135, COSY, HSQC and HMBC (Fig. 2, S1a-c & Table S1). The long 
range correlation between the H1''' and coumarin ring C4' in the 
HMBC spectrum indicates that the C1''' was linked with the 4'-
OH of novobiocin (Fig. 2).  
Coumarin ring 7 (Table S2) and 4-hydroxy-3(3-methylbut--enyl) 
benzoic acid 8 (Table S3) were obtained by acid hydrolysis of 
novobiocin following reported procedures, but with slight 
modification as shown in the experimental section.25 Coupling was 
performed using Steglich esterification reaction employing 1-Ethyl-3-
(3dimethylaminopropyl) to obtain aminocoumarin 9 with 62% of 
yield.  The NMR spectrum of 9 showed 4'-OH (br), 7'-OH and NH at 
11.73, 10.52 and 9.44 ppm respectively (Fig. S2, Table S4). The long-
range heteronuclear (H-C) correlations between 7'-OH and C7', and 
C8' and C9' and NH coupled to C4' and C1 supported the assignment 
and also indicated the formation of the amide bond (Fig. S2c). 
 
Journal Name  
ARTICLE 
This journal is © The Royal Society of Chemistry 20xx J. Name., 2013, 00, 1-3 | 3  
Please do not adjust margins 
Please do not adjust margins 
 
Figure 2. Synthesis of compound 1. Top: Synthesis scheme. Bottom: HMBC NMR assignment of compound 1. Long range coupling 
between H1''' and C4' (Red 4'). It also shows the coupling between C4'''/C6''' and C8''' (red 8'''). 
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Figure 3. Scheme to synthesis of compound 4 & 5 (inset, top left, analytical LC-MS spectrum of compound 10 &11).  
Nucleophilic substitution reaction between compound 9 and the 
photoaffinity labelling regent precursor 6 resulted in two compounds 
(Fig. 3, inset, S3 & S4) with desired product masses (Fig. S3d, S3e, 
S4e, S4f) of 4'- and 7'- linked products. Preparative HPLC indeed 
separated those two compounds, the one with lower retention time 
(95 min, data not shown) was characterised to be the 4'-O compound 
10 (Fig. 3, S3a-c and Table S5,) with the evidence of H1'' coupled to 
C4' in HMBC (Fig. S3b). However, the fraction at 100 min was 
surprisingly not the expected 7'-O-compound as the NMR did not 
show evidence of linkage to the 7'-C position (Fig. S4b). The 7'-OH 
and NH protons were still present in the 1H-NMR (Fig. S4, Table S6). 
The spectrum showed a shift for H1'' from 3.3 ppm to 5.5 ppm and 
coupling to a carbon atom in a very similar position to C4' (Fig. S4d), 
which was shown to be C2'. These results indicated that there is an 
equilibrium between the 4' and 2' positions in the coumarin ring and 
that compound 11 is linked to the 2'-OH in the enol form. 
It is worth noting that conventional catalysts for glycosylation, such 
as Ag2O, Ag2CO3, AgOTf, TMSOTf and Hg(CN)2, did not work 
efficiently with glycosyl acceptors 10 and 11 (data not shown). Here 
we adopted a different route employing phase transfer glycosylation 
reaction. An optimised reaction condition was obtained by 
conducting a number of experiments using varying reactant ratios, 
catalyst equivalents, base concentrations, organic solvents and even 
solid phase transfer conditions (these investigations will be reported 
in future paper). Phase transfer glucosylation of compound 11 using 
Benzyl-tri-butyl ammonium bromide (BTAB) gave 12 (Fig. S5, Table 
S7) with the glucose moiety linked with the 7'-OH of the coumarin 
ring. The disappearance of the 7'-OH signal and the coupling 
between H1''' and C7' demonstrated the correct assignment (Fig. 
S5a-c). But, under the same conditions, glucosylation of compound 
10 gave two different compounds (Fig. S6) which are probably due to 
early activation of diazirine. Analytical LC/MS data showed that 
glucosylation happened but under such conditions, the compound 
lost N2 to form a radical, which led to either an insertion reaction 
(938, [M+H]+, Fig. S6b); or the removal of one additional acetyl group 
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(896, [M+H]+, Fig. S6c). Possible structures are proposed in Fig. S6b 
and S6c based on the MS data and mechanism. 
Since directly coupling compound 6 to the 7'-OH position of 
the coumarin was not possible, an alternative approach was 
adopted by changing the sequence of reactions. Reaction of 
compound 9 with sugar donor 13 gave the expected product 14 
(Fig. 4, S7, Table S8) and a di-glucosyl product (data not shown). 
Compound 14 reacted with PAL precursor 6 to give compound 
15 at moderate yield (Fig. S8, Table S9). 
 
Figure 4. Synthesis of compound 2 & 3
Deprotection of the acetyl groups using NaOMe was slow and 
step by step deacetylation was observed and confirmed by 
LC/MS, e.g. with one acetyl group (Fig. S9c&f) four acetyl group 
(Fig. S9c&g) being observed. In addition, cleavage of the 
glycoside bond was also observed (Fig. S9c&h) with the mass of 
592 in negative mode probably due to unavoidable basic 
conditions caused by trace amount of water. The deprotection 
of compound 15 gave the desired compound 2 (Fig. S9a-c, Table 
S10) as well as compound 3 (Fig. S10, Table S11). Compound 4 
(Fig. S11, Table S12) and 5 (Fig. S12, Table S13) were obtained 
by deprotecting compounds 12 and 10, respectively.  
Conclusions 
In conclusion, the synthesis of five glucosyl-novobiocin based 
PALs was achieved in six steps. This accentuates that the phase 
transfer glycosylation is an effective way of for the 
incorporation of sugar moieties to molecules of interest with 
difficulties in conventional glycosylation methods. The 
structures have been confirmed by different NMR technology. 
This strategy of glucosyl-novobiocin modification provides a 
valuable approach for further development of enhanced 
glucosyl novobiocin mimetic. Preliminary data indicate the 
binding between Hsp90 CTD with compound 1. and tandem MS 
analysis indicated the exact peptide the PAL binds to. This 
method provide an effective synthetic route for multifunctional 
compounds, and a concise chemical biology tool to probe 
protein unknown binding pocket SAR. 
Experimental Section 
 
General experiment details 
Unless otherwise stated, all reactions were carried out in anhydrous 
condition.  Reactions were monitored by thin layer chromatography 
(TLC) and/or a Shimadzu single quadrupole LC/MS.  Flash column 
chromatography was performed on Merck silica Gel 60 (particle size 
40-63µm).  1HNMR and 13CNMR spectra  were  obtained using Bruker 
400 MHz or a Bruker 500 MHz spectrometers.  Multiplicity is 
abbreviated as follows (br = broad, s = singlet, d = doublet, dd = 
double doublet, t = triplet, m = multiplet, etc.) and coupling constants 
were obtained in Hertz. Assignments were aided by DEPT 90, DEPT 
135, COSY, NOESY, HSQC and HMBC.  High resolution mass spectra 
were obtained using Water Q-Tof MS. Chemicals were purchased 
from Sigma-Aldrich.  
 
General procedure for phase transfer glycosylation 
Brominated glycosyl donor (1.1-3.0 equiv), glycosyl acceptor (1 
equiv.) and benzyl tributyl ammonium bromide (0.2 equiv.) in 
dichloromethane (DCM, 10 mL) was stirred for 5 min at room 
temperature. The 0.1 M NaHCO3 (6 mL) was then introduced to the 
reaction mixture. The reaction mixture was stirred for specified time 
at room temperature.  Upon completion (as indicated by TLC and 
LC/MS), the aqueous phase was washed with DCM (3 × 30 ml). The 
dichloromethane extracts were combined and washed with 
saturated NaHCO3 (2 × 30 ml), water (2 × 30 ml) and dried (MgSO4), 
filtered and solvents removed in vacuo to give the corresponding 
glycosides. The crude material was purified by column 
chromatography (ethyl acetate: hexane 1:2 to 1:3 v:v depending on 
the product) then by preparative HPLC using methods 1-3. 
 
HPLC purification methods 
Waters 2555 pump and 2489 UV detector with Waters C-18 (25 × 200 
mm) column. Solvent A 0.1% TFA in Water, Solvent B 0.1% TFA in 
MeOH.  Flow rate: 10 mL/min. Three methods, HPLC-1 (100 min), 
HPLC-2 (175 min) and HPLC-3 (255 min).  
HPLC-1: t=0 min, 30% B, t=90 min, 95% B, t=100 min, 95% B, 
t=101 min, 30% B, t=105 min, 30% B.  
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HPLC-2: t=0 min, 30% B, t=170 min, 95% B, t=175 min, 95% B, 
t=176 min, 30% B, t=177 min, 30% B.  
HPLC-3: t=0 min, 30% B, t=250 min, 95% B, t=255 min, 95% B, 
t=256 min, 30% B, t=257 min, 30% B.  
 
Deprotection of acetate 
To a solution of the acetylated compound (1 mmol) in dry methanol 
(10 ml vol. based on acetate groups) was added sodium methoxide 
(0.1 mmol). The mixture was stirred at room temperature and 
monitored by LC/MS. The reaction mixture was neutralised with a 
drop of acetic acid, stirred for 0.5 hr. The reaction mixture was 
filtered and concentrated under reduced pressure and then purified 
by preparative HPLC. 
 
4-(4-(3-(trifluoromethyl)-3H-diazirin-3-yl)phenyl)methanyl-
novobiocin (1) 
Novobiocin sodium salt and 3-(4-(bromomethyl)phenyl)-3-
(trifluoromethyl)-3H-diazirine (88 mg, 0.316 mmol) were dissolved in 
5 ml of anhydrous DMF under the protection of nitrogen. The 
mixture was protected from light and stirred vigorously at room 
temperature for 16h. The solvent were removed under vacuum and 
syrup was purified by flash chromatography (ethyl acetate, Rf = 0.5) 
to yield compound 1 as pale yellow solid (120mg, 47%). [α]D20: -
130.5, (ACN).1HNMR (400 MHz, MeOD4): δ = 7.55 (1 H, s, H3), 6.69 
(1 H, d, J = 8.9 Hz, H6),  7.51 (1 H, d, J = 8.4 Hz, H7), 3.21 (2 H, m, H8), 
5.20 (1 H, t, J = 7.4 Hz, H9), 1.60 (6H, s, H11, H12), 7.50 (1 H, d, J = 7.4 
Hz, H5'), 6.88 (1 H, d, J = 8.4 Hz, H6'), 1.81 (3 H, s, H11'), 5.41 (1 H, s, 
H1''), 4.12 (1 H, s, H2''), 5.15 (1 H, d, J = 10.8 Hz, H3''), 3.46 (1 H, d, J 
= 10.8 Hz, H4''), 1.18 (3 H, s, H6''), 0.93 (3 H, s, H7''); 3.42 (3 H, s, H8''); 
3.33 (2 H, d, J = 11.8, 36.9 Hz, H1'''), 6.96 (2 H, d, J = 7.9 Hz, H3''', 
H7'''), 6.81 (2 H, d, J = 7.9 Hz, H4''', H6'''). 13CNMR (125 MHz, MeOD4): 
δ = 169.70 (C1), 123.89 (C2), 130.91 (C3), 129.71 (C4), 160.6 (C5), 
115.43 (C6), 128.51(C7), 29.33 (C8), 123.40 (C9), 133.50 (C10), 
26.10(C11), 17.93 (C12), 191.50 (C2'), 69.34 (C3'), 170.30 (C4'), 
126.60 (C5'), 111.25 (C6'), 162.50 (C7'), 115.33 (C8'), 154.10 (C9'), 
116.21 (C10'), 8.30 (C11'), 100.07 (C1''), 71.01 (C2''), 72.96 (C3''), 
82.55 (C4''), 80.34 (C5''), 29.34 (C6''), 22.92 (C7''), 62.08 (C8''), 159.17 
(C9''), 43.90 (C1'''), 127.34 (C2'''), 131.94 (C3'''), 129.72 (C4''')135.31 
(C5'''), 127.34 (C6'''), 131.94 (C7'''), 29.10 (C8'''), 123.20 (C9'''). 
ESI+811 [M+H]+, HRMS: 811.2767, calculated for C40H42F3N4O11: 
811.2802. 
 
3-amino-4,7-dihydroxy-8-methyl-2H-chromen-2-one (7) 
Novobiocin sodium salt (20 g, 0.0315 mol) was dissolved into a 
mixture of pyridine and acetic anhydride (5:1, 240 mL), and 
heated under reflux for 4 hours. After being cooled to room 
temperature, the mixture was then acidified with 5N-HCl drop 
by drop, the pH was monitored by the pH paper (pH=1) and the 
temperature of the reaction mixture was kept below 25°C by ice 
bath. Then the brown syrup precipitated, the aqueous phase 
was decanted. The brown syrup was washed with a small 
amount of diethyl ether (liquid kept for compound 8), and later 
the precipitation of the crude product was collected. The crude 
product was further washed by diethyl ether again (liquid kept 
for compound 8) until getting the light grey powder (9.5 g, 69%): 
Rf =0.13, petroleum ether/ethyl acetic 1:2 v/v. The above solid 
(7.0 g, 0.03 mol) was dissolved in anhydrous methanol (105 mL) 
and 10 % HCl/methanol (190 mL) and the mixture was refluxed 
for 2 hrs. The clear black solution obtained was evaporated in 
vacuo until precipitation started, then kept the reaction mixture 
at 4 oC overnight. The precipitation was filtered and washed 
with ice cold methanol to give the light grey powder. Then the 
filtrate was evaporated again and the procedure was repeated 
twice, and afforded the yellow solid (5.9 g, 95 %).  Rf= 0.15, 
chloroform: methanol 4:1 v/v. 1HNMR (400 MHz, MeOD4): δ = 
7.77 (1 H, d, J = 8.03 Hz, H5), 6.95 (1 H, d, J = 8.56 Hz, H6), 2.28 
(3 H, s, H11). 13CNMR (125 MHz, MeOD4): δ = 164.2 (C2), 96.2 
(C3), 161.7 (C4), 122.6 (C5), 113.7 (C6), 162.3 (C7), 113.5 (C8), 
153.6 (C9), 108.1 (C10), 9.2 (C11). ESI+208 [M+H]+. 
 
Synthesis of 4-acetoxy-3-(3-methylbut-2-en-1-yl)benzoic acid (8) 
The filtrate from above procedure was concentrated to get light 
brown syrup and was extracted using ethyl acetate (3 × 25 ml) 
and with dilute hydrochloric acid (3 × 20 ml of a 3% aqueous 
solution).  The organic extracts were combined and washed 
sequentially with saturated aqueous solution of NaHCO3 (2 × 20 
ml) and water (2 × 20 ml).  The combined organic extracts were 
dried over magnesium sulphate, filtered and concentrated in 
vacuo and purified via column chromatography(petroleum 
ether:ethyl acetate 80:20) to  afford white crystalline powder 
(1.2 g, 16 %). 1HNMR (500 MHz, CDCl3): δ =  8.03 (1H, s, H3), 7.17 
(1H, d, J = 8.3 Hz, H6), 8.01 (1H, d, J = 8.3 Hz, H7), 3.31 (2H, d, J 
= 7.4 Hz, H8), 5.28 (1H, t, J = 7.1 Hz, H9), 1.79 (3H, s, H11), 1.75 
(3H, s, H12), 2.34 (3H, s, H14). 13CNMR (125 MHz, CDCl3): δ = 
171.8 (C1), 127.1(C2), 132.3 (C-3), 129.3 (C4), 163.4 (C5), 123.6 
(C6), 129.5 (C7), 29.3 (C8), 121.0 (C9), 134.1 (C10), 26.3 (C11), 
17.7 (C12) 168.9 (C13), 21.0 (C14). ESI+ 249 [M+H]+. 
 
Synthesis of 4-((4,7-dihydroxy-8-methyl-2-oxo-2H-chromen-3-
yl)carbamoyl)-2-(3-methylbut-2-en-1-yl)phenyl acetate (9) 
Compound 7 (1.0 g, 4.8 mmol) was dissolved in a mixture of 
anhydrous dichloromethane and pyridine (7:3). Then the N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide hydrochloride (EDCI, 
1.0 g, 5.2 mmol) and the compound 8 was added dropwise dissolved 
in a mixture of DCM:pyridine (84:36) and stirred at room 
temperature under nitrogen. After 12 hrs of reaction was washed 
with aq. NaHCO3 (30 ml) and water (30 mL × 2), the  organic phase 
was obtained and the excess solvent was removed in vacuo and the 
residue was purified via solid chromatography (petroleum ether: 
ethyl acetate, 3:1) to afford a yellow solid (1.3 g, 62%). 1HNMR(500 
MHz, DMSO-d6): δ = 7.90 (1H, s, H3), 7.22 (1H, d, J =  8.1 Hz, H6), 7.89 
(1H, d, J =  8.1 Hz, H7), 3.28 (2H, d, J =  7.1 Hz, H8), 5.22 (1H, t, J =  6.8 
Hz, H9), 1.71 (6H, s, H11, H12), 2.33 (3H, s, H14), 7.61 (1H, d, J =  8.1 
Hz, H5'), 6.90 (1H, d, J =  8.1 Hz, H6'), 2.19 (3H, s, H11'), 11.73 (1H, br, 
4'-OH), 10.52 (1H, s, 7'-OH), 9.44 (1H, s, NH). 13CNMR(125 MHz, 
DMSO-d6): δ =165.94 (C1), 133.13 (C2), 129.96 (C3), 132.50 (C4), 
150.99 (C5), 122.44 (C6), 126.94 (C7), 28.99 (C8), 121.55 (C9), 131.75 
(C10), 26.36 (C11),  18.51 (C12), 168.89 (C13), 21.26 (C14), 160.57 
(C2'), 99.72 (C3'), 160.85 (C4'), 121.52 (C5'), 111.83 (C6'), 159.10 
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(C7'), 110.43 (C8'), 151.47 (C9'), 108.07 (C10'), 8.88 (C11'). HMBC: NH 
linked with C4' and C1. ESI+ 438 ([M+H]+). HRMS 438.1552, calculated 
438.1553 (C24H24NO7). 
 
4-((7-hydroxy-8-methyl-2-oxo-4-((4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)oxy)-2H-chromen-3-yl)carbamoyl)-2-(3-
methylbut-2-en-1-yl)phenyl acetate (10) 
To an oven dried flask equipped with magnetic stirrer bar, 
rubber septa and a nitrogen inlet, compound 9 (0.2 g, 0.45 
mmol) and 10 mL of anhydrous DMF were added. The solution 
was cooled to 0oC and sodium hydride (4.2 mg of 60% mineral 
oil dispersion) was added, allowed the reaction mixture to stir 
for 30 min at 0oC. Compound 6(0.14 g, 0.49 mmol) dissolved in 
DMF was added drop wise to the reaction flask.  The reaction 
was allowed to slowly warm up to room temperature and was 
stirred for 72 h).  The reaction mixture was then extracted with 
ethyl acetate (2 × 20 ml) and water.  The combined organic 
extracts was dried over magnesium sulfate.  The drying agent 
was filtered off and the organic extract was concentrated in 
vacuo to give the compound as yellow foam. The desired 
products was isolated via preparative HPLC-1 with retention 
time of 95 min and freeze dried to obtain a light yellow solid 
(0.12 g, 42 %). 1HNMR (500 MHz, DMSO-d6): δ = 7.86 (1H, s, H3), 
7.34 (1H, d, J =  8.2 Hz, H6), 7.92 (1H, d, J =  8.8 Hz, H7), 3.34 (2H, 
d, J =  7.6 Hz, H8), 5.28 (1H, t, J =  7.1 Hz, H9), 1.79 (3H, s, H11), 
1.77(3H, s, H12), 2.42 (3H, s, H14), 7.51 (1H, d, J =  9.5 Hz, H5'), 
6.77 (1H, d, J =  8.9 Hz, H6'), 1.90 (3H, s, H11'), 3.4 (2H, m, H1''), 
7.21 (2H, d, J =  7.6 Hz, H3'', H7''), 7.09 (2H, d, J =  7.6 Hz, H4'', 
H6''), 10.96 (1H, s, 7'-OH), 9.93 (1H, s, NH). 13CNMR(125 MHz, 
DMSO-d6): δ = 166.05 (C1), 129.46 (C2), 129.82 (C3), 133.61 
(C4), 151.56 (C5), 122.84 (C6), 126.72 (C7), 28.92 (C8), 121.24 
(C9), 132.80 (C10), 26.06 (C11), 18.45 (C12), 169.90 (C13), 8.19 
(C14), 188.40 (C2'), 67.69 (C3'), 167.57 (C4'), 125.24 (C5'), 
112.05 (C6'), 163.17 (C7'), 111.78 (C8'), 152.69 (C9'), 110.68 
(C10'), 7.49 (C11'). 42.4 (C1''), 126.84 (C2''), 130.78 (C3''), 
125.87 (C4''), 134.30 (C5''), 125.87 (C6''), 130.78 (C7''), 
28.43(C8''), 123.76 (C9''). HMBC: NH linked with C4' and C1. ESI+ 
636 [M+H]+. HRMS: 636.1959, calculated for C33H29F3N3O7: 
636.1958. 
 
4-((7-hydroxy-8-methyl-4-oxo-2-((4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)oxy)-4H-chromen-3-yl)carbamoyl)-2-(3-
methylbut-2-en-1-yl)phenyl acetate (11) 
To an oven dried flask equipped with magnetic stirrer bar, 
rubber septa and a nitrogen inlet, compound 9 (0.2 g, 0.45 
mmol) and 10 mL of anhydrous DMF were added. The solution 
was cooled to 0oC and sodium hydride (4.2 mg of 60% mineral 
oil dispersion) was added, allowed the reaction mixture to stir 
for 30 min at 0oC. Compound 6(0.14 g, 0.49 mmol) dissolved in 
DMF was added drop wise to the reaction flask.  The reaction 
was allowed to slowly warm up to room temperature and was 
stirred for 72 h).  The reaction mixture was then extracted with 
ethyl acetate (2 × 20 ml) and water.  The combined organic 
extracts was dried over magnesium sulfate.  The drying agent 
was filtered off and the organic extract was concentrated in 
vacuo to give the compound as yellow foam. The desired 
products was isolated via preparative HPLC-1 with a retention 
time of 100 min and freeze dried to obtain a light yellow solid 
(0.09 g, 31 %). 1HNMR (500 MHz, DMSO-d6): δ = 7.83 (1H, s, H3), 
7.22 (1H, d, J =  8.8 Hz, H6), 7.82 (1H, d, J =  5.8 Hz, H7), 3.27 (2H, 
d, J =  7.4 Hz, H8), 5.20 (1H, t, J =  5.7 Hz, H9), 1.69 (6H, s, H11, 
H12), 2.33 (3H, s, H14), 7.50 (1H, d, J =  8.9 Hz, H5'), 6.90 (1H, d, 
J =  8.8 Hz, H6'), 2.19 (3H, s, H11'), 5.46 (2H, s, H1''), 7.55 (2H, d, 
J =  8.1 Hz, H3'', H7''), 7.27 (2H, d, J =  7.5 Hz, H4'', H6''). 
13CNMR(125 MHz, DMSO-d6): δ = 166.23 (C1), 131.17 (C2), 
129.70 (C3), 133.49 (C4), 151.38 (C5), 122.76 (C6), 126.62 (C7), 
28.39 (C8), 121.34 (C9), 132.63 (C10), 25.36 (C11), 17.59 (C12), 
168.90 (C13), 20.81 (C14), 160.97 (C2'), 48.71 (C3'), 161.16 (C4'), 
121.75 (C5'), 112.27 (C6'), 159.37 (C7'), 108.52 (C8'), 150.83 
(C9'), 110.66 (C10'), 8.12 (C11'). 73.10 (C1''), 127.50 (C2''), 
128.52 (C3''), 126.62 (C4''), 138.46 (C5''), 126.62 (C6''), 128.52 
(C7''), 28.56 (C8''), 124.0 (C9''). HMBC: H1'' liked with C2'. ESI+ 
636 [M+H]+. HRMS: 636.1963, calculated for C33H29F3N3O7: 
636.1958. 
 
(2S,3R,5R,6R)-2-((3-(4-acetoxy-3-(3-methylbut-2-en-1-
yl)benzamido)-8-methyl-4-oxo-2-((4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)oxy)-4H-chromen-7-yl)oxy)-6-
(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate  
(12) 
Compound 11 (0.05 g, 0.07 mmol) was reacted with glucosyl 
bromide (compound 13, 0.12 g, 0.30 mmol, 3 equiv.) using the 
general phase transfer glycosylation procedure (in DCM) for 13 
days. The product was purified by preparative HPLC-2 with a 
retention time of 96 min afford compound 12 as a colourless 
white powder  (LCMS yield : 52 %,  isolated yield, 0.02 g, 31 %). 
[α]D20: -22.41, (CHCl3).1HNMR (500 MHz, CDCl3): δ = 7.88 (1H, 
d, J = 2.33 Hz, H3), 7.20 (1H, d, J =  8.33 Hz, H6), 7.82 (1H, dd, J 
=  2.46, 9.49 Hz, H7), 3.34 (2H, d, J =  7.02 Hz, H8), 5.25 (1H, m, 
H9), 1.79 (3H, s, H11), 1.75 (3H, s, H12), 2.38 (3H, s, H14), 7.70 
(1H, d, J =  9.02 Hz, H5'), 7.01 (1H, d, J =  9.07 Hz, H6'), 2.29 (3H, 
s, H11'), 5.38 (2H, s, H1''), 7.50 (2H, d, J =  8.60 Hz, H3'', H7''), 
7.21 (2H, d, J =  8.21 Hz, H4'', H6''), 5.15 (1H, d, J = 7.68 Hz, H1'''), 
5.39 (1H, m, H2'''), 5.36 (1H, m, H3'''), 5.24 (1H, m, H4'''), 3.93 
(1H, m, H5'''), 4.34 (1H, m, H6a'''), 4.22 (1H, m, H6b'''), 2.09-2.11 
(12 H, s, 4 * CH3CO), 7.75 (1H, s, NH).  13CNMR(125 MHz, CDCl3): 
δ = 166.62 (C1), 130.82 (C2), 129.97 (C3), 134.78 (C4), 152.50 
(C5), 123.11 (C6), 126.38 (C7), 28.92 (C8), 120.78 (C9), 134.27 
(C10), 25.71 (C11), 17.90 (C12), 168.98 (C13), 20.82 (C14), 
157.78 (C2'), 104.95 (C3'), 162.43 (C4'), 122.03 (C5'), 111.62 
(C6'), 157.33 (C7'), 116.11 (C8'), 150.00 (C9'), 113.19 (C10'), 8.4 
(C11'). 72.49 (C1''), 129.64 (C2''), 128.26 (C3''), 126.82 (C4''), 
137.73 (C5''), 126.82 (C6''), 128.26 (C7''), 28.19 (C8''), 122.6 
(C9''), 99.22 (C1'''), 70.89 (C2'''), 72.18 (C3'''), 68.22 (C4'''), 72.23 
(C5''') 62.01 (C6a'''), 62.01 (C6b'''), 20.69 (4 * CH3CO),  170.51 
(CH3CO), 170.22 (CH3CO), 169.41 (CH3CO), 169.21 
(CH3CO).HMBC: H1''' linked with C7' and H1'' lined with C2'. ESI+ 
966 [M+H]+. HRMS: 7966.2873, calculated for C47H47F3N3O16: 
966.2873. 
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Glycosylation of compound 10 
The same procedure was followed in the synthesis of compound 
12, i.e. Compound 10 (0.05 g, 0.07 mmol) was reacted with 
glucosyl bromide (compound 13, 0.12 g, 0.30 mmol, 3 equiv.) 
using the general phase transfer glycosylation procedure (in 
DCM) for 13 days. However, no desired glycosylation product 
formed but new reactions with N2 removal and possible insert 
reactions were discovered by LC/MS. 
 
(2S,3R,5R,6R)-2-((3-(4-acetoxy-3-(3-methylbut-2-en-1-
yl)benzamido)-7-hydroxy-8-methyl-2-oxo-2H-chromen-4-yl)oxy)-6-
(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyl triacetate (14) 
Compound 9 (0.3 g, 0.68  mmol) was reacted with glucosyl 
bromide (13, 0.84 g, 2.0 mmol) using the general phase transfer 
glycosylation procedure (in DCM) for 7 days. The product was 
purified by preparative HPLC-2 with a retention time of 112 min 
to afford compound 14 as a white powder  (0.10 g, 19%). [α]D20: 
-66.03, (CHCl3). 1HNMR (500 MHz, CDCl3): δ = 7.95 (1H, s, H3), 
7.23 (1H, d, J =  9.15 Hz, H6), 7.87 (1H, d, J =  8.56 Hz, H7), 3.37 
(2H, d, J =  7.85 Hz, H8), 5.27 (1H, m, H9), 1.79 (3H, s, H11), 1.76 
(3H, s, H12), 2.38 (3H, s, H14), 7.35 (1H, d, J =  9.18 Hz, H5'), 6.75 
(1H, d, J =  9.21 Hz, H6'), 2.21 (3H, s, H11'), 5.36 (1H, m, H1''), 
5.36 (1H, m, H2''), 5.24 (1H, m, H3''), 5.12 (1H, t, J = 9.39 Hz, 
H4''), 3.64 (1H, m, H5''), 4.17 (1H, m, H6a''), 4.24 (1H, m, H6b''), 
2.00-2.07 (12 H, s, 4 * CH3CO), 7.81 (1H, s, NH).  13CNMR(125 
MHz, CDCl3): δ = 167.51 (C1), 130.57 (C2), 130.19 (C3), 134.87 
(C4), 152.49 (C5), 123.00 (C6), 126.49 (C7), 29.05 (C8), 120.79 
(C9), 134.06 (C10), 25.76 (C11), 17.96 (C12), 168.85 (C13), 20.55 
(C14), 157.55 (C2'), 107.02 (C3'), 160.98 (C4'), 121.41 (C5'), 
112.64 (C6'), 158.71 (C7'), 109.01 (C8'), 151.16 (C9'), 112.10 
(C10'), 8.08 (C11'). 98.95 (C1''), 71.20 (C2''), 72.35 (C3''), 67.98 
(C4''), 72.57 (C5'') 61.49 (C6''), 20.54-20.63 (4 * CH3CO),  170.56 
(CH3CO), 170.05 (CH3CO), 169.39 (CH3CO), 169.33 (CH3CO). ESI- 
766 [M-H]-. HRMS: 768.2504, calculated for C38H42NO16: 
768.2504. 
 
(3R,5R,6R)-2-((3-(4-acetoxy-3-(3-methylbut-2-en-1-yl)benzamido)-
8-methyl-2-oxo-7-((4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzyl)oxy)-2H-chromen-4-yl)oxy)-6-
(acetoxymethyl)tetrahydro-2H-pyran-3,4,5-triyltriacetate (15) 
To an oven dried flask equipped with magnetic stirrer bar, 
rubber septa and a nitrogen inlet, compound 14 (0.05 g, 0.07 
mmol) and 10 mL of anhydrous DMF were added. The solution 
was cooled to 0oC and sodium hydride (2.1 mg of 60% mineral 
oil dispersion) was added, allowed the reaction mixture to stir 
for 30 min at 0oC. Compound 6 (0.02g, 0.08mmol) dissolved in 
DMF was added drop wise to the reaction flask.  The reaction 
was allowed to slowly warm up to room temperature and was 
stirred for 20 h.  The reaction mixture was then extracted with 
ethyl acetate (2 × 20 ml) and water.  The combined organic 
extracts was dried over magnesium sulfate. The drying agent 
was filtered off and the organic extract was concentrated in 
vacuo to give the compound as yellow foam. The desired 
products was isolated via preparative HPLC-2 with a retention 
of 160 min and freeze dried to obtain a light yellow solid (LCMS 
yield : 35 %,  isolated yield, 0.02 g, 34 %). [α]D20: -43.73, (CHCl3). 
1HNMR (500 MHz, CDCl3): δ = 7.89 (1H, s, H3), 7.20 (1H, d, J =  
8.42 Hz, H6), 7.83 (1H, d, J =  8.91 Hz, H7), 3.34 (2H, d, J =  7.02 
Hz, H8), 5.26 (1H, m, H9), 1.78 (3H, s, H11), 1.75 (3H, s, H12), 
2.34 (3H, s, H14), 7.63 (1H, d, J =  9.22 Hz, H5'), 6.90 (1H, d, J =  
8.76 Hz, H6'), 2.29 (3H, s, H11'), 5.23 (2H, s, H1''), 7.50 (2H, d, J 
=  8.64 Hz, H3'', H7''), 7.26 (2H, d, J =  8.21 Hz, H4'', H6''), 5.40 
(1H, d, J = 8.63Hz, H1'''), 5.36 (1H, t, J = 7.90 Hz, H2'''), 5.22 (1H, 
m, H3'''), 5.13 (1H, t, J = 8.77 Hz, H4'''), 3.64 (1H, m, H5'''), 4.13 
(1H, dd, J = 5.69, 12.8 Hz, H6a'''), 3.90 (1H, dd, J = 2.13, 12.09 
Hz, H6b'''), 1.96-2.03 (12 H, s, 4 * CH3CO). 13CNMR(125 MHz, 
CDCl3): δ = 166.50 (C1), 130.84 (C2), 129.95 (C3), 134.77 (C4), 
152.29 (C5), 122.98 (C6), 126.32 (C7), 28.93 (C8), 120.77 (C9), 
134.12 (C10), 25.75 (C11), 18.00 (C12), 168.84 (C13), 20.89 
(C14), 161.29 (C2'), 106.98 (C3'), 156.61 (C4'), 122.08 (C5'), 
108.63 (C6'), 159.49 (C7'), 114.54 (C8'), 150.58 (C9'), 110.65 
(C10'), 8.48 (C11'). 69.67 (C1''), 129.03 (C2''), 127.42 (C3''), 
126.89 (C4''), 138.08 (C5''), 126.89 (C6''), 127.42 (C7''), 28.56 
(C8''), 117.37 (C9''), 98.57 (C1'''), 71.15 (C2'''), 72.34 (C3'''), 
67.86 (C4'''), 72.46 (C5'''), 61.34 (C6'''), 20.53-20.62 (4 * CH3CO),  
170.34 (CH3CO), 169.98 (CH3CO), 169.52 (CH3CO), 169.33 
(CH3CO). HMBC: H1''' linked with C4' and H1'' lined with C7'. ESI+ 
1953 [2M+Na+]+. HRMS: 966.2930, calculated for C47H47F3N3O16: 
966.2908. 
 
4-hydroxy-N-(8-methyl-2-oxo-7-((4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)oxy)-4-(((3R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-3-yl)-
3-(3-methylbut-2-en-1-yl)benzamide (2) and 4-hydroxy-N-(4-
hydroxy-8-methyl-2-oxo-7-((4-(3-(trifluoromethyl)-3H-diazirin-3-
yl)benzyl)oxy)-2H-chromen-3-yl)-3-(3-methylbut-2-en-1-
yl)benzamide (3) 
Compound 15 (0.02 g, 0.02 mmol) was reacted with sodium 
methoxide (catalytic percentage) using the general acetate 
deprotection procedure (in CH3OH) for 26 h. The product was 
purified by preparative HPLC-3 with a retention of 201 min to afford 
compound 2 as a white powder  (1.2mg, 7.9 %) and 256 min for 
compound 3 as white powder (3 mg, 11%).  
compound 2: [α]D20: -66.7, (CHCl3). 1HNMR (500 MHz, MeOD4): δ = 
7.82 (1H, s, H3), 6.87 (1H, d, J =  8.63 Hz, H6), 7.77 (1H, d, J =  8.61 Hz, 
H7), 3.42 (2H, m, H8), 5.38 (1H, m, H9), 1.77 (6H, s, H11, H12), 7.97 
(1H, d, J =  8.61 Hz, H5'), 7.12 (1H, d, J =  7.75 Hz, H6'), 2.38 (3H, s, 
H11'), 5.33 (2H, s, H1''), 7.63 (2H, d, J =  7.75 Hz, H3'', H7''), 7.33 (2H, 
d, J =  8.62 Hz, H4'', H6''), 5.22 (1H, d, J = 8.82 Hz, H1'''), 3.49 (1H, m, 
H2'''), 3.30 (1H, m, H3'''), 3.36 (1H, m, H4'''), 3.12 (1H, m, H5'''), 3.68 
(1H, d, J = 11.8 Hz, H6a'''), 3.52 (1H, m, H6b'''). 13CNMR(125 MHz, 
MeOD4): δ = 170.34 (C1), 125.26 (C2), 130.98 (C3), 129.96 (C4), 
160.66 (C5), 115.53 (C6), 128.52 (C7), 29.33 (C8), 123.41 (C9), 133.57 
(C10), 26.1 (C11), 18.0 (C12), 168.84 (C13), 163.09 (C2'), 108.87 (C3'), 
161.14 (C4'), 124.12 (C5'), 110.06 (C6'), 160.88 (C7'), 114.92 (C8'), 
152.38 (C9'), 111.92 (C10'), 8.4 (C11'). 70.82 (C1''), 129.71 (C2''), 
129.04 (C3''), 127.92 (C4''), 140.59 (C5''), 127.92 (C6''), 129.04 (C7''), 
29.41 (C8''), 123.75 (C9''), 103.76 (C1'''), 75.35 (C2'''), 77.74 (C3'''), 
70.82 (C4'''), 78.76 (C5'''), 61.96 (C6'''). HMBC: H1''' linked with C4' 
and H1'' lined with C7'. ESI- 754 [M-H]-. HRMS:756.2365,  calculated 
for C37H37F3N3O11: 756.2380.  
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Compound 3: 
1HNMR (500 MHz, MeOD4): δ = 7.61 (1H, s, H3), 6.78 (1H, d, J =  8.99 
Hz, H6), 7.61 (1H, d, m, H7), 3.30 (2H, d, 7.64, H8), 5.17 (1H, s, H9), 
1.68 (6H, s, H11, H12), 7.70 (1H, d, J =  9.13 Hz, H5'), 6.79 (1H, d, J =  
8.67 Hz, H6'), 2.25 (3H, s, H11'), 5.07 (2H, s, H1''), 7.36 (2H, d, J =  9.18 
Hz, H3'', H7''), 7.11 (2H, d, J =  9.18 Hz, H4'', H6''), 13.89 (1H, s, 4'-
OH), 8.60 (1H, s, NH). 13CNMR(125 MHz, MeOD4): δ = 166.95 (C1), 
123.81 (C2), 129.92 (C3), 127.58 (C4), 158.97 (C5), 116.22 (C6), 
127.64 (C7), 29.77 (C8), 120.59 (C9), 136.27 (C10), 25.82 (C11), 18.11 
(C12), 161.76 (C2'), 103.06 (C3'), 153.40 (C4'), 122.57 (C5'), 108.67 
(C6'), 159.12 (C7'), 114.15 (C8'), 149.81 (C9'), 111.07 (C10'), 8.50 
(C11'). 69.91 (C1''), 129.02 (C2''), 127.41 (C3''), 126.85 (C4''), 138.29 
(C5''), 126.85 (C6''), 127.41 (C7''), 28.70 (C8''), 122.10 (C9''). HMBC: 
H1'' lined with C7'. ESI- 592 [M-H]-. HRMS: 594.1842, calculated for 
C31H27F3N3O6: 594.1852.  
 
4-hydroxy-N-(8-methyl-4-oxo-2-((4-(3-(trifluoromethyl)-3H-
diazirin-3-yl)benzyl)oxy)-7-(((2S,3R,5S,6R)-3,4,5-trihydroxy-6-
(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-3-yl)-
3-(3-methylbut-2-en-1-yl)benzamide (4) 
Compound 12 (0.01 g, 0.01 mmol) was reacted with sodium 
methoxide (catalytic percentage) using the general acetate 
deprotection procedure (in CH3OH) for 22 h. The product was 
purified by preparative HPLC-3 with a retention time of 136 min to 
afford compound 4 as a white powder (1.2mg,7.9 %).[α]D20: -41.9 
(ACN).1HNMR (500 MHz, MeOD4): δ = 7.79 (1H, s, H3), 6.87 (1H, d, J 
=  6.4 Hz, H6), 7.70 (1H, m, H7), 3.4 (2H, m, H8), 5.38 (1H, m, H9), 1.76 
(6H, s, H11, H12), 7.97 (1H, d, J =  8.61 Hz, H5'), 6.85 (1H, d, J =  6.3 
Hz, H6'), 2.39 (3H, s, H11'), 5.51 (2H, d, J = 3.3 Hz, H1''), 7.48 (2H, m, 
H3'', H7''), 7.23 (2H, d, J =  7.23 Hz, H4'', H6''), 5.06 (1H, d, J = 7.9 Hz, 
H1'''), 3.56 (1H, m, H2'''), 3.49 (1H, m, H3'''), 3.46 (1H, m, H4'''), 3.41 
(1H, m, H5'''), 3.92 (1H, d, J = 12.15 Hz, H6a'''), 3.72 (1H, dd, J = 5.5, 
12.15 Hz, H6b'''), 7.71 (1H, s, NH). 13CNMR(125 MHz, MeOD4): δ = 
164.0 (C1), 131.2 (C2), 131.0 (C3), 133.7 (C4), 148.6 (C5), 123.40 (C6), 
128.47 (C7), 29.32 (C8), 123.39 (C9), 135.5 (C10), 26.00 (C11), 17.96 
(C12), 163.81 (C2'), 105.9 (C3'), 164.2 (C4'), 127.99 (C5'), 115.53 (C6'), 
160.53 (C7'), 116.3 (C8'), 154.4 (C9'), 112.9 (C10'), 8.63 (C11'). 75.20 
(C1''), 130.4 (C2''), 129.33 (C3''), 112.97 (C4''), 139.8 (C5''), 112.97 
(C6''), 129.33 (C7''), 28.19 (C8''), 126 (C9''), 102.21 (C1'''), 74.86 
(C2'''), 78.17 (C3'''), 71.26 (C4'''), 78.39 (C5'''), 62.52 (C6'''). HMBC: 
H1''' linked with C7' and H1'' lined with C2'. ESI- 755 [M-H]-. HRMS: 
756.2365,  calculated for C37H37F3N3O11: 756.2380. 
 
4-hydroxy-N-(7-hydroxy-8-methyl-2-oxo-4-((4-(3-(trifluoromethyl)-
3H-diazirin-3-yl)benzyl)oxy)-2H-chromen-3-yl)-3-(3-methylbut-2-
en-1-yl)benzamide (5) 
Compound 10(0.01 g, 0.02 mmol) was reacted with sodium 
methoxide (catalytic percentage) using the general acetate 
deprotection procedure (in CH3OH) for 15 h. The product was 
purified by preparative HPLC using 30-95 % methanol water in 
180  min gradient elution to afford compound 5 as a white 
powder  (6.6 mg, 50  %). 1HNMR (500 MHz, DMSO-d6): δ = 7.63 
(1H, d, J = 2.01Hz, H3), 6.83 (1H, d, J =  8.01 Hz, H6), 7.57 (1H, 
m, H7), 3.38 (2H, d, J =  7.51 Hz, H8), 5.31 (1H, m, H9), 1.80 (3H, 
s, H11), 1.70 (3H, s, H12), 2.42 (3H, s, H14), 7.57 (1H, m, H5'), 
6.53 (1H, d, J =  8.61 Hz, H6'), 2.01 (3H, s, H11'), 3.44 (2H, m, 
H1''), 7.13 (2H, d, J =  8.03 Hz, H3'', H7''), 7.00 (2H, d, J =  8.03 
Hz, H4'', H6''). 13CNMR(125 MHz, DMSO-d6): δ = 162.3 (C1), 
127.5 (C2), 130.0 (C3), 127.5 (C4), 158.4 (C5), 115.7 (C6), 127.4 
(C7), 25.8 (C8), 120.9 (C9), 135.7 (C10), 29.5 (C11), 18.1 (C12), 
169.90 (C13), 8.19 (C14), 188.9 (C2'), 67.4 (C3'), 168.0 (C4'), 
127.5 (C5'), 112.1 (C6'), 162.1 (C7'), 112.3 (C8'), 153.4 (C9'), 
126.0 (C10'), 8.0 (C11'). 43.3 (C1''), 129.2 (C2''), 130.5 (C3''), 
126.5 (C4''), 132.8 (C5''), 126.5 (C6''), 130.5 (C7''), 43.0 (C8''), 
120.6 (C9''). HMBC: 1'' lined with C4'. ESI+ 594 [M+H]+; HRMS: 
594.1863,  calculated for C31H27F3N3O6: 594.1852. 
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